

## Daily News



Published by:



DAY 2

## News AT A GLANCE



CPHI India positions pharma industry for...

Page No. 12



AI-integrated dissolution systems...

Page No. 14



Barentz India charts path to outpace...

Page No. 20



Crius Group bets on predictive AI and global...

Page No. 30

## 18<sup>th</sup> edition of CPHI & PMEC India opens, uniting global leaders to shape pharma's future

OUR BUREAU, MUMBAI

HE sold-out 18th edition of CPHI & PMEC India, organised by Informa Markets in India, opened its doors at the India Expo Centre, Greater Noida, Delhi-NCR, showcasing the robust potential of India's pharmaceutical industry. Bringing together over

2,000 exhibitors and 50,000 visitors from more than 120 countries, including China, Italy, Germany, Switzerland, and South Korea, the expo serves as a dynamic hub for innovation and collaboration. Spanning pharma machinery, packaging, analytical instruments, lab & analytical equipment, cleanroom technology, laboratory technologies, ingredi-

ents, and beyond, it offers a comprehensive platform for stakeholders to engage in transformative dialogues and foster strategic partnerships.

From 2026 onward, CPHI and PMEC India will transition into two specialised shows across two locations on consecutive days—a decision shaped by

CONTINUED ON p4▶





## **PHARMA BUZZ**



THE expiry of GLP-1 patents opens a defining window for India—not just to scale generics, but to shape the future of global metabolic health. As a country, our strength has always been accessibility with quality, and this next wave demands both scientific precision and responsible innovation. At Dr. Morepen, we see this shift not merely as a market opportunity, but as a chance to empower millions with reliable, affordable solutions for diabetes and weight management. As someone deeply committed to fitness and preventive health, I believe India can lead this movement with discipline, integrity, and purpose.



Varun Suri, Chief Executive Officer, Dr Morepen



NDIA'S GLP 1 moment is arriving: with semaglutide's core composition patent expiring in early 2026 in India, a generics wave is built to cut costs and expand access, positioning the country for leadership across APIs, formulations, and devices. Beyond big pharma, India's startup engine—now the world's third largest ecosystem—adds speed and ingenuity to this transition, from peptide CDMOs to AI enabled process optimization and novel delivery platforms.


What tips the scales is convergence: peptide manufacturing scale up by Indian CDMOs, GLP 1 pipeline moves by local majors, and venture interest in deep tech pharma, all aligned to the 2026

patent cliff. Startups can fill critical gaps—process intensification, device innovation, and digital pharmacovigilance—accelerating compliant, affordable GLP 1 generics for domestic and export markets. Challenges remain around follow on formulation/device patents and litigation, but coordinated industry startup collaboration can compress timelines and costs, helping India translate patent expiry into durable global share.

It comes as a very big opportunity for Indian pharmaceutical industries specially the startups sectors to rise with this changing scenario!

Dr. Forum Gandhi, Quality Assurance-Director, Shreenath Chemicals

NDIA is well placed, but it's not automatic. As GLP-1 patents expire, global demand will explode, and India already has a strong insulin and peptide manufacturing base, cost advantages, and a proven generics ecosystem.





If Indian firms move beyond pure cost play into innovation- long-acting formulations, fixed-dose combos, drug—device integration- India can absolutely emerge as a leading GLP-1 generics hub, but competition from China and Western CDMOs will be fierce.

Dr. Sanjay Agrawal, Scientific Advisor of ALKOMEX GBN PHARMA USA